Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating women who have refractory metastatic breast cancer.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Phase II Evaluation of Pyrazoloacridine (NSC #366140) in Patients With Metastatic Breast Cancer|
|Study Start Date:||July 1997|
|Study Completion Date:||January 2002|
OBJECTIVES: I. Determine the efficacy of pyrazoloacridine in patients with refractory breast cancer. II. Determine the toxic effects of pyrazoloacridine in these patients.
OUTLINE: Patients receive pyrazoloacridine IV over 3 hours. Treatment repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 1 year.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003041
|United States, Kentucky|
|Central Baptist Hospital|
|Lexington, Kentucky, United States, 40503|
|United States, Ohio|
|Arthur G. James Cancer Hospital - Ohio State University|
|Columbus, Ohio, United States, 43210|
|Grant/Riverside Methodist Hospitals|
|Columbus, Ohio, United States, 43214|
|Columbus, Ohio, United States, 43222|
|United States, South Carolina|
|Cancer Centers of the Carolinas|
|Greenville, South Carolina, United States, 29605|
|Study Chair:||Eric H. Kraut, MD||Ohio State University Comprehensive Cancer Center|